ACL Laboratories
Now part of ADVOCATEHEALTH

Test Bulletin

July 2023

ACL Implements New Lipase Reagents Resulting in Significant Reference Range Change

Effective Tuesday, August 1, 2023, ACL Laboratories will be implementing new Lipase reagents from our current vendor. With the new assay formulation and standardization there will be a significant change in the reference range for Lipase. ACL Lipase results will be more in line with textbook reference ranges and the ranges employed by other laboratories.

Test Name	Test Order Code	NEW Reference Range Effective August 1, 2023	Current Reference Range
Lipase	LAB8269	15 – 77 U/L	73 - 393 U/L
Lipase, Fluid	LAB10063	N/A – No Reference Range	N/A – No Reference Range

Due to the significance of this change, the following statements will be appended to each Lipase result for 30 days after the change.

Test Name	Test Order Code	Appended Statement
Lipase	LAB8269	Test performed on updated Lipase method. Reference ranges differ from the previous method.
Lipase, Fluid	LAB10063	Values differ from the previous method.

For additional information regarding this test, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at acllaboratories.com/test-catalog/.

New Orderable Code for 17-Hydroxyprogesterone, Neonatal/Infant

Effective Tuesday, July 18, 2023, 17-Hydroxyprogesterone, Neonatal/Infant (Test Order Code LAB11690) is available as an orderable test code with testing being performed at Quest Diagnostics. This assay will provide a faster turnaround time for neonatal and infant patient populations being evaluated for congenital adrenal hyperplasia. Providers and clients will no longer have to utilize a Miscellaneous test code for ordering. Test information is below.

Test Information	17-Hydroxyprogesterone, Neonatal/Infant Test Order Code LAB11690
Specimen Type	Serum
Collection Tube	Red Top
Temperature	Refrigerated
Stability	10 days
Methodology	Immunochemiluminometric Assay (ICMA)
TAT	5-8 days
Performing Lab	Quest Diagnostics

Updates to Hypersensitivity Pneumonitis Orderable Codes

Effective Tuesday, July 18, 2023, Hypersensitivity Pneumonitis, 2 (Test Order Code LAB9611) has been deactivated. Providers will have access to two orderable codes for the evaluation of hypersensitivity pneumonitis. Please see below for additional details on available testing going forward.

	Hypersensitivity Pneumonitis 1	Hypersensitivity Pneumonitis Panel (Available after 5 PM on July 18, 2023)
Test Order Code	LAB11637	LAB11740
Performing Lab	ARUP	ARUP
Specimen Type	Serum	Serum
Collection Tube	Gold gel	Gold gel
Temperature	Refrigerated	Refrigerated
Stability	2 weeks	2 weeks
Methodology	Qualitative Immunodiffusion	Qualitative Immunodiffusion
TAT	5-9 days	5-9 days
Components	Aspergillus fumigatus #1 Aspergillus fumigatus #6 Aureobasidium pullulans Pigeon Serum Micropolyspora faeni	Aspergillus fumigatus #1 Aspergillus fumigatus #6 Aureobasidium pullulans Pigeon Serum Micropolyspora faeni Aspergillus flavus Aspergillus fumigatus #2 Aspergillus fumigatus #3 Saccharomonospora viridis Thermoactinomyces candidus

Updated Referral Testing Orderable Codes

Effective Tuesday, July 18, 2023, the following send out assays have been updated.

Cytomegalovirus (CMV) Drug Resistance

	Deactivated July 18, 2023	Replacement Activated July 18, 2023
Test Name	CMV Antiviral Drug Resistance	Cytomegalovirus Drug Resistance by Next Generation Sequencing, Ganciclovir, Foscarnet, Cidofovir, Maribavir, and Letermovir
Test Order Code	LAB9450	LAB11757
Performing Lab	ARUP	ARUP
Specimen Type	Plasma	Plasma
Collection Tube	Lavender (EDTA) or pink (K2EDTA)	Lavender (EDTA), pink (K2EDTA), or plasma preparation tube
Temperature	Frozen	Frozen
Stability	1 month	1 month
Methodology	Sequencing	Massively Parallel Sequencing
TAT	Within 5 days	Up to 11 days

Fungal Antibodies with Reflex to Blastomyces

	Deactivated July 18, 2023	Replacement Activated July 18, 2023
Test Name	Fungal Antibodies, Complement Fixation	Fungal Antibodies with Reflex to Blastomyces
Test Order Code	LAB9544	LAB11753
Performing Lab	CCL (referred secondarily to ARUP)	ARUP
Specimen Type	Serum	Serum
Collection Tube	Gold gel	Gold gel
Temperature	Refrigerated	Refrigerated
Stability	2 weeks	2 weeks
Methodology	Semi-Quantitative Complement Fixation/Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)/Qualitative Immunodiffusion	Semi-Quantitative Complement Fixation/ Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)/Qualitative Immunodiffusion
TAT	5-9 days	4-7 days

Deactivation of Unusual Organism Culture (Test Order Code LAB9562)

Effective Tuesday, July 18, 2023, ACL Laboratories discontinued Test Order Code LAB9562, "Unusual Organism Culture, *Haemophilus ducreyi."* This testing was discontinued by the previous reference laboratory and is not currently performed within ACL or at any other reference laboratories currently utilized by ACL. **Effective Tuesday, July 18, 2023,** ACL Laboratories will no longer offer an option for detection of *H. ducreyi.*

In lieu of a definitive diagnostic test for *H. ducreyi,* ACL Laboratories would direct providers to the 2021 US Centers for Disease Control and Prevention's criteria for probable diagnosis of *H. ducreyi* (chancroid) infection[1]:

1) The patient has one or more painful genital ulcers
2) The clinical presentation, appearance of genital ulcers and, if present, regional lymphadenopathy are typical for chancroid
3) The patient has no evidence of *Treponema pallidum* (syphilis) infection by direct detection or serologic testing (serologic testing must be performed at least 7-14 days after ulcer onset)
4) The ulcers are negative for the presence of herpes simplex virus 1or 2 (HSV-1 or HSV-2).

ACL apologizes for any inconvenience that this may cause providers or their patients. Please contact ACL Laboratories Client Services Department at (414) 328-7900 with any questions regarding this change.

References:

[1] Workowski KA, et al, 2021. Sexually Transmitted Infections Guidelines, 2021. Morbidity and Mortality Weekly Report. **70(4)** https://www.cdc.gov/std/treatment-guidelines/STI-Guidelines-2021.pdf

Created: 07/2023 | Created by: H. Barrie – ACL Business Development | Designed by: K. Voskuil – KV Graphics